Latest Search
Quote
| Back Zoom + Zoom - Top | ||||
|
CSPC PHARMA Signs Exclusive License Agreement with AstraZeneca to Receive US$100M Upfront Payment
Recommend 2 Positive 10 Negative 5 |
||||
|
||||
|
CSPC PHARMA (01093.HK) announced that it has entered into an exclusive license agreement with AstraZeneca (AZN.US) to develop, manufacture, and commercialize the group's Lipoprotein(a) (Lp(a)) inhibitor, YS2302018, worldwide, and any pharmaceutical or biological product subsequently developed that is comprised of or contains that compound. Under the terms of the agreement, the group agreed to grant an exclusive license to AstraZeneca to develop, manufacture, and commercialize the compound and the products worldwide. The group will receive an upfront payment of US$100 million, and is also eligible to receive up to US$370 million in potential development milestone payments and up to US$1.55 billion in potential sales milestone payments, plus tiered royalties based on annual net sales of the products. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
